Gene expression trend changes in breast cancer populations over two decades: insights from The Cancer Genome Atlas database
Open Access
- 22 March 2022
- journal article
- research article
- Published by Springer Nature in Hereditas
- Vol. 159 (1) , 1-11
Abstract
Background: Breast cancer has remained the most common malignancy in women over the past two decades. As lifestyle and living environments have changed, alterations to the disease spectrum have inevitably occurred in this time. As molecular profiling has become a routine diagnostic and objective indicator of breast cancer etiology, we analyzed changes in gene expression in breast cancer populations over two decades using The Cancer Genome Atlas database. Methods: We performed Heatmap and Venn diagram analyses to identify constantly up- and down-regulated genes in breast cancer patients of this cohort. We used Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses to visualize associated functional pathways. Results: We determined that three oncogenes, PD-L2, ETV5, and MTOR and 113 long intergenic non-coding RNAs (lincRNAs) were constantly up-regulated, whereas two oncogenes, BCR and GTF2I, one tumor suppression gene MEN1, and 30 lincRNAs were constantly down-regulated. Up-regulated genes were enriched in “focal adhesion” and “PI3K-Akt signaling” pathways, etc., and down-regulated genes were significantly enriched in “metabolic pathways” and “viral myocarditis”. Eight up-regulated genes exhibited doubled or higher expression and the expression of three down-regulated genes was halved or lowered and correlated with long-term survival. Conclusions: In this study, we found that gene expression and molecular pathway enrichments are constantly changing with time, importantly, some altered genes were associated with prognostics and are potential therapeutic targets, suggesting that the current molecular subtyping system must be updated to keep pace with this dynamic change.Keywords
All Related Versions
Funding Information
- National Natural Science Foundation of China (92059105)
- National Key Research and Development Program of China (2021YFE0203200)
- Natural Science Foundation of Beijing Municipality (7202212)
- Research and Development Funds of Peking University People's Hospital (RDY2020-16)
- Young Investigator Program of Peking University Health Science Center (BMU2021PYB013)
This publication has 88 references indexed in Scilit:
- The Cancer Genome Atlas Pan-Cancer analysis projectNature Genetics, 2013
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trialThe Lancet, 2013
- Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO StudyJournal of Clinical Oncology, 2012
- Proteoglycans in cancer biology, tumour microenvironment and angiogenesisJournal of Cellular and Molecular Medicine, 2011
- Exposure to Phthalates and Breast Cancer Risk in Northern MexicoEnvironmental Health Perspectives, 2010
- Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor–Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20Journal of Clinical Oncology, 2010
- Focal adhesion kinase: A prominent determinant in breast cancer initiation, progression and metastasisCancer Letters, 2010
- Biological Functions of the Genes in the Mammaprint Breast Cancer Profile Reflect the Hallmarks of CancerBiomarker Insights, 2010
- Supervised Risk Predictor of Breast Cancer Based on Intrinsic SubtypesJournal of Clinical Oncology, 2009
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerNew England Journal of Medicine, 2002